**Core Concept**
Malignant glaucoma is a rare and serious complication of cataract surgery, characterized by a shallow or flat anterior chamber, increased intraocular pressure (IOP), and a fixed mid-dilated pupil. It is caused by a misdirected aqueous humor flow, leading to a posterior displacement of the lens-iris diaphragm.

**Why the Correct Answer is Right**
Treatment of malignant glaucoma involves correcting the posterior displacement of the lens-iris diaphragm by increasing the depth of the anterior chamber. This is achieved by using medications that decrease the vitreous volume and increase the aqueous humor production. The correct answer, **C. Pilocarpine with a miotic effect and a carbonic anhydrase inhibitor**, is a combination of a miotic agent (pilocarpine) that helps in reducing the vitreous volume and a carbonic anhydrase inhibitor (e.g., acetazolamide) that increases the aqueous humor production.

**Why Each Wrong Option is Incorrect**
* **Option A:** is incorrect because atropine is a mydriatic agent that would worsen the condition by increasing the posterior displacement of the lens-iris diaphragm.
* **Option B:** is incorrect because a hyperosmotic agent (e.g., mannitol) would decrease the vitreous volume but would not address the underlying cause of the malignant glaucoma.

**Clinical Pearl / High-Yield Fact**
In cases of malignant glaucoma, it is essential to remember that the treatment should aim at correcting the posterior displacement of the lens-iris diaphragm and not just reducing the intraocular pressure.

**Correct Answer:** C. Pilocarpine with a miotic effect and a carbonic anhydrase inhibitor.